Neoprobe signs distribution deal with Syncor International (US)
This article was originally published in Clinica
Executive Summary
Syncor International (US) is to distribute Neoprobe's RIGScan cancer detection radiopharmaceuticals in North America and other selected countries. Neoprobe plans to prepare marketing submissions for its first RIGScan product, CR49, in the US by the end of this year, with European dossiers ready for the first quarter of 1996. The RIGScan CR49 is a radiolabelled monoclonal antibody which targets specific antigens produced by colorectal cancer.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.